Catalog No.
RMA30301
Expression system
Mammalian Cells
Species reactivity
Mouse
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Target
TNFSF11, OPGL, ODF, RANKL, TRANCE, Tumor necrosis factor ligand superfamily member 11, Osteoclast differentiation factor, Osteoprotegerin ligand, Receptor activator of nuclear factor kappa-B ligand, TNF-related activation-induced cytokine, CD254
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O35235
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
7C6
Target tolerance improvement of the immunogenicity assay developed for analysing samples from clinical trials of RGB-14, a proposed biosimilar to Prolia/Xgeva., PMID:40368321
Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial., PMID:40350430
Inhibition of RANKL is critical for accurate assessment of anti-drug antibody incidence to denosumab in clinical studies., PMID:40220951
Visualization and quantification of RANK-RANKL binding for application to disease investigations and drug discovery., PMID:40147673
Alterations of bone proteins in medication-related osteonecrosis of the jaw., PMID:39972547
RANK/RANKL Signaling Pathway in Breast Development and Cancer., PMID:39821032
Establishing patient-derived tumor organoids of bone metastasis from lung adenocarcinoma reveals the transcriptomic changes underlying denosumab treatment., PMID:39739069
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of HLX14 versus reference denosumab in healthy males: A randomized phase I study., PMID:39700054
Are the Soluble Receptors sRAGE, sRANKL, and Osteoprotegerin Associated with Anemia in Rheumatoid Arthritis?, PMID:39684440
In silicon desinging of RANKL-targeting vaccine for protection of osteoporosis based on the epitope of Denosumab., PMID:39580862
The Notch1 signaling pathway directly modulates the human RANKL-induced osteoclastogenesis., PMID:38040752
Denosumab Attenuates Glucolipotoxicity-Induced β-Cell Dysfunction and Apoptosis by Attenuating RANK/RANKL Signals., PMID:37373436
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial., PMID:36892190
Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption., PMID:36543965
Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial., PMID:36535121
Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma., PMID:36104102
Effect of abatacept treatment on serum osteoclast-related biomarkers in patients with rheumatoid arthritis (RA): A multicenter RA ultrasound prospective cohort in Japan., PMID:34260539
Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL., PMID:34112702
RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway., PMID:34108600
Management of Myeloma Bone Lesions., PMID:33806209
Is denosumab associated with an increased risk for infection in patients with low bone mineral density? A systematic review and meta-analysis of randomized controlled trials., PMID:33793076
ETS1 polymorphism rs73013527 in relation to serum RANKL levels among patients with RA., PMID:33592912
The Non-Bone-Related Role of RANK/RANKL Signaling in Cancer., PMID:33119864
Antimicrobial peptide gene expression in medication-related osteonecrosis of the jaw., PMID:33065485
Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-κB Ligand with a Superior Therapeutic Index., PMID:32955874
Chondroblastoma Expresses RANKL by RNA In Situ Hybridization and May Respond to Denosumab Therapy., PMID:32826531
Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction., PMID:32732353
Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone., PMID:32539628
TNF Receptor: Fc Fusion Protein Downregulates RANKL/OPG Ratio by Inhibiting CXCL16/CXCR6 in Active Ankylosing Spondylitis., PMID:32116188
Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer., PMID:31992773
Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)., PMID:31856909
Histone H3.3 mutation in giant cell tumor of bone: an update in pathology., PMID:31748824
LOX-1 is involved in TLR2 induced RANKL regulation in peri-implantitis., PMID:31655342
HTLV-1 viral oncogene HBZ drives bone destruction in adult T cell leukemia., PMID:31578308
Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?, PMID:31268745
Excess of second tumors in denosumab-treated patients: a metabolic hypothesis., PMID:31237145
Expression Profiling of Receptor-Activator of Nuclear Factor-Kappa B Ligand in Soft Tissue Tumors., PMID:31189751
Neoadjuvant and Adjuvant Treatment with Denosumab in Aggressive Giant-cell Tumor of Bone in the Proximal Fibula: a Case Report., PMID:31188771
Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases., PMID:31187176
CD21-/low B cells associate with joint damage in rheumatoid arthritis patients., PMID:31141193
RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass., PMID:31120440
Expression of the RANK/RANKL/OPG system in the human intervertebral disc: implication for the pathogenesis of intervertebral disc degeneration., PMID:31101043
Thrombospondin enhances RANKL-dependent osteoclastogenesis and facilitates lung cancer bone metastasis., PMID:31075265
Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial., PMID:31036625
Osteoimmunology of Bone Loss in Inflammatory Rheumatic Diseases., PMID:31001277
Giant Cell Lesions of the Maxillofacial Skeleton Express RANKL by RNA In Situ Hybridization Regardless of Histologic Pattern., PMID:30998511
The RANKL-RANK Axis: A Bone to Thymus Round Trip., PMID:30984193
Effector memory regulatory T cells were most effective at suppressing RANKL but their frequency was downregulated in tibial fracture patients with delayed union., PMID:30946855
Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden., PMID:30496606
Dynamics of Bone Cell Interactions and Differential Responses to PTH and Antibody-Based Therapies., PMID:30460589
For research use only. Not for human or drug use.
